Significant improvements in patient management have been achieved, however, with the development of targeted small molecules including tyrosine kinase inhibitors (TKIs) such as sunitinib, sorafenib, pazopanib, and axitinib [7]-[9].
Other major advances in analgesia and sedation management have been achieved through optimizing the use of newer and older medications through novel treatment strategies, which have been demonstrated in prospective trials to improve outcomes such as duration of mechanical ventilation.
In children, short-term weight loss/weight management success has been achieved in controlled clinical and research settings [ 4, 5]; however, long-term success is rare, adherence is low, and studies outside of these settings often lack comparison groups and clinical outcomes other than body weight and body mass index (BMI) [ 6].
Research from an engineering management perspective has focused the technical failings in project management, but little has been achieved in improving performance.
This improvement in short-term prognosis over time suggests that substantial progress has been achieved in the management and/or selection of critically ill cirrhotic candidates for ICU.
In spite of considerable advances in the treatment of the intestinal symptoms, comparatively less progress has been achieved in the management of CF lung disease.
Significant progress has been achieved in the management of patients with colon cancer in both age groups, but trends have been more noticeable in patients aged 75 years and above.
In contrast to the progress seen in the molecular classification, pathogenesis elucidation and management of quite a few neoplasms, little has been achieved towards personalized approach in the NPC field so far.
Rapid progress has been achieved recently in the management of chronic lymphocytic leukaemia (CLL).
Even though considerable progress has been achieved over the past years, management of diabetes and its complications remains a major challenge.
